Amphastar P (AMPH)vsAstraZeneca PLC (AZN)
AMPH
Amphastar P
$21.78
+5.56%
HEALTHCARE · Cap: $927.72M
AZN
AstraZeneca PLC
$190.95
-0.56%
HEALTHCARE · Cap: $284.30B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 8288% more annual revenue ($60.44B vs $720.53M). AZN leads profitability with a 17.2% profit margin vs 11.0%. AZN appears more attractively valued with a PEG of 1.38. AZN earns a higher WallStSmart Score of 64/100 (C+).
AMPH
Buy50
out of 100
Grade: C-
AZN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+9.6%
Fair Value
$31.64
Current Price
$21.78
$9.86 discount
Margin of Safety
+5.9%
Fair Value
$194.57
Current Price
$190.95
$3.62 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Attractively priced relative to earnings
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Areas to Watch
0.4% revenue growth
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
Moderate valuation
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AMPH
The strongest argument for AMPH centers on Price/Book, P/E Ratio.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : AMPH
The primary concerns for AMPH are Revenue Growth, Market Cap, Piotroski F-Score.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Key Dynamics to Monitor
AMPH profiles as a value stock while AZN is a mature play — different risk/reward profiles.
AMPH carries more volatility with a beta of 0.90 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 50/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amphastar P
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company is headquartered in Rancho Cucamonga, California.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?